Novartis hands its TB program to nonprofit; BioMed looks west for R&D real estate;

@FierceBiotech: Sanofi wins FDA's blessing for an oral Gaucher drug. News | Follow @FierceBiotech

@JohnCFierce: Top trending story, 2 days now: Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market. Report | Follow @JohnCFierce

@DamianFierce: $FOLD CEO on positive new migalastat data, next-gen Fabry treatment and the importance of perseverance. Report | Follow @DamianFierce

@EmilyMFierce: Viral inducers plus antibodies thwart latent HIV in mice. FierceBiotech Research story | Follow @EmilyMFierce

> Novartis ($NVS) has signed a deal to hand over its whole tuberculosis program to TB Alliance, a nonprofit drug developer funded in part by the Bill & Melinda Gates Foundation. More

> BioMed Realty, a life sciences real estate outfit, is expanding out west, planning to construct a 122,000-square-foot facility in Seattle and establish an R&D campus on the 19-acre former home of Life Technologies in Foster City, CA. Seattle | California

> AstraZeneca ($AZN) is pairing up with Japan's Mitsubishi Tanabe Pharma on a three-year collaboration to identify new treatments for diabetic nephropathy. News

Medical Device News

@FierceMedDev: VC Rock Health partners with Abbott, expands digital health portfolio. Story | Follow @FierceMedDev

@StacyALawrence: Abbott gets $20M from DoD to develop portable concussion test. More | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA targets off-label use of intranasal splint, with safety alert and Class I recall notice. Article | Follow @VarunSaxena2

@EmilyWFierce: Scientists at Biomeme developing a portable, real-time PCR machine that runs lab tests through a smartphone. Story via Wired | Follow @EmilyWFierce

> Boston Sci to develop two new guidewires with cardiological indications by 2015. Story

> Survey says people want neurological diagnosis, regardless of cure. More

> ConvaTec weighs plans for inversion deal amid rumors of 2015 sale. Article

Pharma News

@FiercePharma: Top-read on FP Tues: Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion. Report | Follow @FiercePharma

@TracyStaton: Been on vacay? @FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. More | Follow @TracyStaton

@EricPFierce: FDA warning letter for India's Marck Biosciences lays out in vivid detail why it banned it plant. Article | Follow @EricPFierce

@CarlyHFierce: Merck taps celeb chef to deliver diabetes message to Hispanics. Story | Follow @CarlyHFierce

> Depomed scores a win in its epic struggle to fend off Gralise copycats. Article

> Celgene's cost-sharing offer persuades NICE to about-face on Revlimid. Story

> Most of pharma's 2014 woes playing out as execs expected. More

Drug Delivery News

> Hydrogel enables longer graft survival in hand, leg transplant patients. Article

> Russian scientists close in on drug-delivering nanorobots. Story

> Study finds blood-brain barrier opening can be controlled, enabling enhanced drug delivery. More

> Mist formulation of Boehringer Ingelheim's COPD inhaler gets advisory committee nod. Story

> Scientists uncover new drug delivery method using nanosecond lasers and carbon nanotubes. Article

Diagnostics News

> Blood test for drug-resistant malaria strain shows promise. Report

> Two tests better than one to spot harmful mold infection. Story

> Cancer Genetics boosts Medicare coverage for DNA-based cancer Dx. More

> LabCorp jumps into prenatal Dx market already packed with rivals. Story

> Investors become ambivalent to Biocept's Dx commercialization plans. Article

Pharma Marketing News

> Celgene cost-sharing deal sways NICE to greenlight new Revlimid use. News

> When is 5 years not 5 years? When it's the FDA counting, Eisai claims. Report

> AbbVie aims to truck ahead with hep C testing promo campaign. More

> Hardest-charging drugs this year? They're not just Sovaldi and Olysio. Story

> Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.